Autologous and allogeneic high-dose therapy for melanoma

被引：2

作者：

Margolin K.A. ^{[1
]}

机构：

[1] City of Hope National Medical Center, 1500 East Duarte Road, Duarte, 91010, CA

来源：

Current Oncology Reports | 2001年 / 3卷 / 4期

关键词：

Advanced Melanoma; Donor Lymphocyte Infusion; Melanoma; Metastatic Melanoma; Vitiligo;

D O I：

10.1007/s11912-001-0087-3

中图分类号：

学科分类号：

摘要：

Opportunities for the treatment of melanoma with high-dose chemotherapy have been inadequately explored because of the failure of early studies to demonstrate an advantage for high doses of those agents with disease activity that could also be safely dose-escalated without excessive extramedullary toxicities. However, emerging concepts of tumor and transplantation immunology have recently coincided, providing the rationale for new strategies that exploit principles of allogeneic transplant to overcome immunologic tolerance and escape mechanisms in the tumor-bearing individual. It is hoped that this setting will provide an improved milieu for donor-derived immunotherapeutic intervention that takes advantage of shared tumor antigens with therapeutic potential shown in a variety of tumor vaccination studies. © 2001, Current Science Inc.

引用

页码：338 / 343

页数：5

共 43 条

[1]

Chu E., DeVita V.T., Principles of cancer management: chemotherapy, Cancer Principles and Practice of Oncology, pp. 289-306, (2001)

[2]

Meyers M.L., Balch C.M., Diagnosis and treatment of metastatic melanoma, Cutaneous Melanoma, pp. 325-372, (1998)

[3]

McDermott D.F., Mier J.W., Lawrence D.P., Et al., A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon a-2B in patients with metastatic melanoma, Clin Cancer Res, 6, pp. 2201-2208, (2000)

[4]

Khayat D., Borel C., Tourani J.M., Et al., Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma, J Clin Oncol, 11, pp. 2179-2180, (1993)

[5]

Legha S.S., Ring S., Eton O., Et al., Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, and dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma, J Clin Oncol, 16, pp. 1752-1759, (1998)

[6]

Richards J.M., Mehta N., Ramming K., Skosey P., Sequential chemoimmuno-therapy in the treatment of metastatic melanoma, J Clin Oncol, 10, pp. 1338-1343, (1992)

[7]

Doroshow J.H., Pharmacological basis for high-dose chemotherapy, Hematopoietic Cell Transplantation, pp. 103-122, (1999)

[8]

Fields K.K., Autologous bone marrow transplantation and melanoma: a focused review of the literature, Ann Plast Surg, 28, pp. 70-73, (1992)

[9]

Sznol M., Emerging concepts in cancer vaccine development, PPO Update 13/7, Cancer, Principles and Practice of Oncology, pp. 1-11, (1999)

[10]

Shu S., Plautz G.E., Krauss J.C., Chang A.E., Tumor immunology, JAMA, 278, pp. 1972-1981, (1997)

← 1 2 3 4 5 →